PMID- 30214637
OWN - NLM
STAT- MEDLINE
DCOM- 20190904
LR  - 20190904
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 8
IP  - 16
DP  - 2018
TI  - AMPK: Potential Therapeutic Target for Ischemic Stroke.
PG  - 4535-4551
LID - 10.7150/thno.25674 [doi]
AB  - 5'-AMP-activated protein kinase (AMPK), a member of the serine/threonine 
      (Ser/Thr) kinase group, is universally distributed in various cells and organs. 
      It is a significant endogenous defensive molecule that responds to harmful 
      stimuli, such as cerebral ischemia, cerebral hemorrhage, and, neurodegenerative 
      diseases (NDD). Cerebral ischemia, which results from insufficient blood flow or 
      the blockage of blood vessels, is a major cause of ischemic stroke. Ischemic 
      stroke has received increased attention due to its '3H' effects, namely high 
      mortality, high morbidity, and high disability. Numerous studies have revealed 
      that activation of AMPK plays a protective role in the brain, whereas its action 
      in ischemic stroke remains elusive and poorly understood. Based on existing 
      evidence, we introduce the basic structure, upstream regulators, and biological 
      roles of AMPK. Second, we analyze the relationship between AMPK and the 
      neurovascular unit (NVU). Third, the actions of AMPK in different phases of 
      ischemia and current therapeutic methods are discussed. Finally, we evaluate 
      existing controversy and provide a detailed analysis, followed by ethical issues, 
      potential directions, and further prospects of AMPK. The information complied 
      here may aid in clinical and basic research of AMPK, which may be a potent drug 
      candidate for ischemic stroke treatment in the future.
FAU - Jiang, Shuai
AU  - Jiang S
AD  - Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry 
      of Education. Faculty of Life Sciences, Northwest University, 229 Taibai North 
      Road, Xi'an 710069, China.
AD  - Department of Aerospace Medicine, The Fourth Military Medical University, 169 
      Changle West Road, Xi'an 710032, China.
FAU - Li, Tian
AU  - Li T
AD  - Department of Biomedical Engineering, The Fourth Military Medical University, 169 
      Changle West Road, Xi'an 710032, China.
FAU - Ji, Ting
AU  - Ji T
AD  - Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry 
      of Education. Faculty of Life Sciences, Northwest University, 229 Taibai North 
      Road, Xi'an 710069, China.
FAU - Yi, Wei
AU  - Yi W
AD  - Department of Cardiovascular Surgery, Xijing Hospital, The Fourth Military 
      Medical University, 127 Changle West Road, Xi'an 710032, China.
FAU - Yang, Zhi
AU  - Yang Z
AD  - Department of Biomedical Engineering, The Fourth Military Medical University, 169 
      Changle West Road, Xi'an 710032, China.
FAU - Wang, Simeng
AU  - Wang S
AD  - Center for Human Nutrition, University of Texas Southwestern Medical Center, 5323 
      Harry Hines Blvd, Dallas, TX 75390, USA.
FAU - Yang, Yang
AU  - Yang Y
AD  - Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry 
      of Education. Faculty of Life Sciences, Northwest University, 229 Taibai North 
      Road, Xi'an 710069, China.
FAU - Gu, Chunhu
AU  - Gu C
AD  - Department of Cardiovascular Surgery, Xijing Hospital, The Fourth Military 
      Medical University, 127 Changle West Road, Xi'an 710032, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180810
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinases/chemistry/genetics/*metabolism
MH  - Animals
MH  - Brain Ischemia/*pathology/physiopathology/*therapy
MH  - Disease Models, Animal
MH  - Humans
MH  - Models, Theoretical
MH  - Molecular Targeted Therapy/*methods
MH  - Stroke/*pathology/physiopathology/*therapy
PMC - PMC6134933
OTO - NOTNLM
OT  - *5'-AMP-activated protein kinase
OT  - *Autophagy
OT  - *Energy metabolism
OT  - *Ischemic stroke
OT  - *Metformin
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2018/09/15 06:00
MHDA- 2019/09/05 06:00
PMCR- 2018/01/01
CRDT- 2018/09/15 06:00
PHST- 2018/02/22 00:00 [received]
PHST- 2018/07/16 00:00 [accepted]
PHST- 2018/09/15 06:00 [entrez]
PHST- 2018/09/15 06:00 [pubmed]
PHST- 2019/09/05 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - thnov08p4535 [pii]
AID - 10.7150/thno.25674 [doi]
PST - epublish
SO  - Theranostics. 2018 Aug 10;8(16):4535-4551. doi: 10.7150/thno.25674. eCollection 
      2018.